ABSTRACT In order to determine the effect of drugs on bronchial hyperreactivity in subjects with asthma, 12 atopic asthmatic volunteers underwent bronchial challenge with either histamine or methacholine on three separate days. Before the challenges no medication was given on the first day, on the second 400 ,ug of aerosol fenoterol and on the third 5 mg of oral fenoterol were administered. The aerosol fenoterol caused the dose response curves to both histamine and methacholine to be shifted to the right in all subjects. The oral dose produced no significant change from the control values. The On the first day a bronchial challenge with methacholine or histamine was performed using the standardised procedure described by Chai et al.7
Fenoterol, a /2-adrenergic agonist has been shown in both oral and aerosol forms to be an effective bronchodilator.1-3 The aerosol form has been shown to protect against exercise-induced asthma (ETA)2 and to prevent early reactions to allergen challenge.3 Oral sympathomimetics appear to be less effective than aerosols in preventing EtA.2 4 Cockcroft et a15 have shown that both inhaled and oral salbutamol will protect against histamine-induced bronchoconstriction, although the aerosol gives greater protection than the oral drug. This difference between oral and aerosol forms may reflect different tissue concentrations of the drug or may indicate that the mechanisms of bronchodilatation and of the prevention of induced bronchoconstriction are different. Orehek et a16 have distinguished two factors in the asthmatic reaction to bronchial challenge. Firstly, sensitivity which is the amount of a provoking agent required to produce a bronchoconstrictor response, and secondly reactivity, the way in which the airways respond to successive doses of the provoking agent. Their data suggest that it is the reactivity which best distinguishes asthmatic from non-asthmatic subjects. The cause of the heightened reactivity in asthma is unknown.
In order to study the post-saline FEV1 Individual log dose response curves were plotted and the dose required to produce a 20 % fall in FEV1 (PD2oFEV1) was recorded. In addition, doseresponse regression equations were calculated for the individual subjects from at least three points between the dose which initiated a consistent fall in FEV1 and the final dose. Correlation coefficients were calculated, and the regression equations were rejected when a significant correlation was not found. The coefficient "a" from the formula, percent fall FEV1 = a log dose + b, was recorded as a measure of the slope of the dose response curve.
Bronchodilator 
tGeometric mean. C = challenge alone, 0 challenge after S mg oral fenoterol, A = challenge after 400 ,ug aerosol fenoterol. PD20 for both the control study and the study after oral fenoterol (p < 0 001, in all cases). After oral fenoterol the PD20 was not significantly different from the control values for both challenges. In some subjects aerosol fenoterol reduced the response to methacholine and histamine challenge so that the maximum challenge dose produced less than a 20% fall in FEV1. In these subjects, PD20 was calculated as greater than the maximum doses (methacholine: 475 units, histamine: 97 units). No value for the slope of the dose-response curves could be calculated for these subjects. The correlation coefficients for the slope of the dose-response curves were significant in all subjects for histamine but for only seven subjects for methacholine (see In all instances where the correlation coefficients were significant, neither aerosol or oral fenoterol altered the slopes of the dose-response curves. In order to show the mean values for the change in position of the curves, the inhalational units causing 10% and 20% changes in FEV1 for the histamine and methacholine challenges have been plotted in fig 2. Figure 3 shows the individual dose-response curves for histamine on the control day and after the aerosol form of the drug. The hatched area indicates the position on the dose-response curve which, in our laboratory, separates people with current or recent clinical asthma from normal people.
Bronchodilator therapy before the challenge did not affect the rate of recovery in the 15 minutes after ( standard error) for all subjects after histamine and methacholine challenge. C = challenge alone (n = 10 histamine and methacholine); 0 = challenge after 5 mg oral fenoterol (n = 10 histamine and methacholine); A = challenge after 400 ug aerosol fenoterol (n = 7 histamine and 8 methacholine).
the challenges. After histamine most subjects were within 13 % and after methacholine within 21 % of their initial values.
Discussion
This study shows that fenoterol administered by aerosol but not by mouth in normal clinical dosage, changes the position of the dose-response curve (reduces the sensitivity) of asthmatic subjects to histamine and methacholine. In these subjects, neither aerosol nororal fenoterol had an effect on the slope ofthe dose-response curve (that is the reactivity) to histamine or methacholine. The design of the study was kept simple and was not done in a double-blind manner because, during previous studies, we have found that subjects invariably know when the active drug has been given. Each subject was simply told that the study was to determine the effect of the drug on his response to bronchial provocation. It was never suggested that one form of administration might have a different effect from the other form.
Juniper et a19 have shown that sensitivity to both histamine and methacholine is highly reproducible in asthmatic subjects. Reactivity is a more variable measurement and is difficult to determine accurately using the present method since several points on the linear part of the curve must be documented. A significant correlation coefficient for the dose response in all subjects given methacholine would probably have been achieved if the doses had been increased more gradually. However, even in these three subjects, the slope was obviously not changed by the drugs.
It appears that the effect of aerosol fenoterol is to shift the dose-response curve to the right, without altering its shape. This confirms the finding of Cockcroft et al5 who showed that the effect of /32 aerosols was to change the position of the doseresponse curve of asthmatic patients to bronchial challenge with histamine, although they did not measure the slope. This study has shown that the effect is produced by simply increasing the threshold of the asthmatic response without changing the slope. Figure 3 shows life. In other words, it appears to shift the response of the airways temporarily from the asthmatic into the non-asthmatic range. Perhaps future drugs being investigated for the treatment of asthma could be studied both for their bronchodilating effect and their ability to protect against provoked attacks. As yet no drug has been shown to alter reactivity as opposed to sensitivity in asthmatic subjects. Further studies of the effect of increasing doses of the aerosol and of the duration of its "protective" action are needed. Tailor-made therapy, to find the dose and frequency of bronchodilator aerosol administration which keeps asthmatic subjects in the non-asthmatic range, might be a logical method of treatment, particularly for subjects with severe disease. 
